首页> 美国卫生研究院文献>PLoS Clinical Trials >SUMO-1 Modification on K166 of PolyQ-Expanded aTaxin-3 Strengthens Its Stability and Increases Its Cytotoxicity
【2h】

SUMO-1 Modification on K166 of PolyQ-Expanded aTaxin-3 Strengthens Its Stability and Increases Its Cytotoxicity

机译:在PolyQ扩展aTaxin-3的K166上进行SUMO-1修饰可增强其稳定性并增加其细胞毒性

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Post-translational modification by SUMO was proposed to modulate the pathogenesis of several neurodegenerative diseases. Spinocerebellar ataxia type 3/Machado-Joseph disease (SCA3/MJD) is an autosomal dominant neurodegenerative disease caused by polyQ-expanded ataxin-3. We have previously shown that ataxin-3 was a new target of SUMOylation in vitro and in vivo. Here we identified that the major SUMO-1 binding site was located on lysine 166. SUMOylation did not influence the subcellular localization, ubiquitination or aggregates formation of mutant-type ataxin-3, but partially increased its stability and the cell apoptosis. Our findings revealed the role of ataxin-3 SUMOylation in SCA3/MJD pathogenesis.
机译:SUMO的翻译后修饰被提议来调节几种神经退行性疾病的发病机理。脊髓小脑性共济失调3型/马查多-约瑟夫病(SCA3 / MJD)是由polyQ扩展的ataxin-3引起的常染色体显性遗传性神经退行性疾病。先前我们已经表明,紫杉醇3是体外和体内SUMOylation的新目标。在这里,我们确定主要的SUMO-1结合位点位于赖氨酸166上。SUMOylation不会影响突变型ataxin-3的亚细胞定位,泛素化或聚集体形成,但会部分增加其稳定性和细胞凋亡。我们的研究结果揭示了taxin-3 SUMOylation在SCA3 / MJD发病机理中的作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号